UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

Nebraska Lymphoma Study Group

Burkitt lymphoma

Established in 1982 by James O. Armitage, MD, the Nebraska Lymphoma Study Group (NLSG) is a unique collaborative effort between community oncologists and pathologists, and their counterparts at UNMC. Through this collaborative effort, patients with Hodgkin’s disease, non-Hodgkin’s lymphoma, and other neoplastic hematologic disorders are treated according to standard, state-of-the-art therapies in the community setting, while being afforded the expertise and high technology of the University setting. 

The majority of the patients enrolled in the study group are previously untreated, and are the most likely to benefit from their therapy. In many cases, fresh tissues are shipped to the Department of Pathology and Microbiology at UNMC for detailed histopathologic, immunologic, and molecular characterization. Cytogenetic studies are also performed.

James O. Armitage, MD and Julie M. Vose, MD direct the NLSG, while Timothy Greiner, MD, leads the Hematopathology Section which reviews all tissues submitted to the NLSG. The important work of the NLSG has lead to national and international recognition of UNMC, as well as its collaborators in the state of Nebraska.

The NLSG brings community oncologists and pathologists and their counterparts at UNMC together to provide the very best in diagnostic and treatment care. Their patients receive state-of-the-art therapies where they live, while accessing the expertise and resources of an academic health sciences center. 

Since 1982, the NLSG has reviewed 68,933 biopsies, procured 8,371 frozen tissue, and collected 6,919 clinical data on de novo patients treated by the NLSG.

Contact Us

Contact Heather Nutsch, Health Data Coordinator II Lead for the Oncology and Hematology Department, by email or phone 402-559-6203.